Rein Therapeutics Statistics
Total Valuation
RNTX has a market cap or net worth of $36.33 million. The enterprise value is $28.90 million.
Important Dates
The next estimated earnings date is Wednesday, August 13, 2025, after market close.
| Earnings Date | Aug 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
RNTX has 22.15 million shares outstanding. The number of shares has increased by 285.32% in one year.
| Current Share Class | 22.15M |
| Shares Outstanding | 22.15M |
| Shares Change (YoY) | +285.32% |
| Shares Change (QoQ) | +1.03% |
| Owned by Insiders (%) | 1.09% |
| Owned by Institutions (%) | 15.08% |
| Float | 18.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 7.40 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.39
| Current Ratio | 1.39 |
| Quick Ratio | 1.24 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -86.78% and return on invested capital (ROIC) is -23.47%.
| Return on Equity (ROE) | -86.78% |
| Return on Assets (ROA) | -21.14% |
| Return on Invested Capital (ROIC) | -23.47% |
| Return on Capital Employed (ROCE) | -51.34% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.57M |
| Employee Count | 11 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -1.54M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.91% in the last 52 weeks. The beta is 1.31, so RNTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | -48.91% |
| 50-Day Moving Average | 1.86 |
| 200-Day Moving Average | 2.42 |
| Relative Strength Index (RSI) | 33.87 |
| Average Volume (20 Days) | 28,664 |
Short Selling Information
The latest short interest is 86,465, so 0.39% of the outstanding shares have been sold short.
| Short Interest | 86,465 |
| Short Previous Month | 113,654 |
| Short % of Shares Out | 0.39% |
| Short % of Float | 0.46% |
| Short Ratio (days to cover) | 1.95 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -26.52M |
| Pretax Income | n/a |
| Net Income | -61.27M |
| EBITDA | -26.50M |
| EBIT | -26.52M |
| Earnings Per Share (EPS) | -$2.87 |
Full Income StatementBalance Sheet
The company has $7.43 million in cash and n/a in debt, giving a net cash position of $7.43 million or $0.34 per share.
| Cash & Cash Equivalents | 7.43M |
| Total Debt | n/a |
| Net Cash | 7.43M |
| Net Cash Per Share | $0.34 |
| Equity (Book Value) | 49.88M |
| Book Value Per Share | 0.22 |
| Working Capital | 2.35M |
Full Balance SheetCash Flow
| Operating Cash Flow | -23.20M |
| Capital Expenditures | n/a |
| Free Cash Flow | -23.20M |
| FCF Per Share | -$1.05 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |